New genital warts ointment

When it comes to treating genital warts, there are several methods available that doctors may employ. However, there doesn't appear to be one type of treatment for genital warts to effectively treat every person that comes down with the disease. In the fight against genital warts, doctors have been performing plenty of research noting possible new treatments for the disease. In this article, we'll take a look at a new treatment that is being developed to give doctors another option when it comes to helping patients with genital warts.

Known as Polyphenon E, this new type of ointment was created by a bio-tech company known as MediGene AG, with the A-G part of the name representing the two countries involved in the research - America and Germany. Based in Frankfurt, the phase 3 trial of testing the drugs has already been completed, and MediGene couldn't be happier about the results. The trial was conducted with over 500 patients that had genital warts who were in 48 different hospitals in 7 different countries. The studying method that was employed for the test was double-blind, meaning that neither the physicians that were applying the treatment nor the patients that were receiving the treatment had absolutely no idea if they were getting the real Polyphenon E or a placebo. This type of study helps to eliminate the possibility of the placebo effect, in which a patient merely believes that a treatment is working, and through that, they feel better.

In the test, the Polyphenon E ointment was applied three times daily for up to sixteen weeks if necessary. The ointment itself is actually made of an extract that is found in the leaves that make up green tea. After the phase 3 test was complete, the results showed that a full fifty three percent of all the tested patients exhibited a complete lack of genital warts by the end of the sixteen weeks. In approximately seventy eight percent of all of the cases, most of the warts were removed. Less than five percent of all the test subjects experienced a recurrence of genital warts within the twelve weeks of follow-up questions posed by the research team.

Since the results of the phase 3 test showed to be of promise, MediGene AG is now planning on performing similar tests in the United States in order to gain approval for the drug. The bio-tech company also feels that the drug may be of merit in helping different problems with the skin as well, and they have figured the potential net earnings from the development of Polyphenon E to be in excess of one hundred million dollars. It's important to remember that the drug has not been completely cleared yet, and there may be some problems with it. However, if the drug is to meet the approval of the Food and Drug Administration of the United States, it may prove to be an effective tool in the arsenal of doctors who are waging war against genital warts.

Genital warts news on the Web